| Name | Title | Contact Details |
|---|
EverZinc is a global leader in producing specialty zinc materials, with a history of over 185 years. Established in 2016, the company became the worlds largest zinc specialty chemical producer after merging with U.S. Zinc in 2022. Headquartered in Houston, Texas, EverZinc operates 14 production sites across North America, Europe, and Asia, employing over 800 people. The company specializes in four main product lines: fine zinc powders, zinc oxide, zinc powders for batteries, and Zano®, an ultra-fine zinc oxide. These products serve various industries, including personal care, pharmaceuticals, chemicals, textiles, agriculture, paints, coatings, and rubber. EverZincs advanced manufacturing technologies and focus on material science support its diverse customer base and contribute to its strong growth in the zinc specialty chemical market.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Bigelow is the M + A Advisor exclusively for owners of high-performing private companies — Entrepreneur Owner-Managers with their skin in the game. Our scrappy boutique firm behaves as one collaborative team. Leveraging our independence and exclusive EOM focus, we have helped hundreds of clients build and capture Enterprise Value while respecting their values, their legacy and the intersection of their professional and personal goals. Frequently our work with clients goes on for years in advance of a wealth-building transaction. Unlike virtually all of the firms with which we compete, we are independently owned. We have only one source of revenue — our Entrepreneur Owner-Manager clients. No referral fees. No investing, trading, lending, or underwriting. No buy-side advisory. No products to sell. No conflicts. We aspire to be completely aligned with achieving our clients potential, striving endlessly to be masters of our craft.
Flynn Group is the largest franchise operator in the United States, focusing on multi-brand restaurant and retail operations. Founded in 1999 by Greg Flynn, the company has expanded significantly from its beginnings as a single-market Applebee’s operator. It now manages a diverse portfolio that includes well-known brands such as Pizza Hut, Taco Bell, Panera Bread, and Arby’s, with over 2,500 locations across the country. The company specializes in franchise management, acquiring and optimizing underperforming locations to enhance operational efficiency and drive sales growth. Flynn Groups acquisition strategy has led to substantial growth, including the recent addition of 45 Pizza Hut locations in 2025, bringing its total to over 1,000. With a people-first approach, Flynn Group emphasizes employee training and retention, ensuring consistent customer experiences across its various dining segments.